Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics develops cancer medicines, with its most advanced candidate in Phase 2/3 trials for melanoma. It last closed at $5.15 on Nov 17, down 4.36% on the day.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on EIKN in the past 90 days. The average target is $23.00, with a high of $23.00 and a low of $23.00, compared with the last close of $5.15.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 16 | HC Wainwright & Co. | Initiated | Buy | $23 |
| Aug 14 | Wedbush | Maintained | Sell | $4 |
Technical Analysis
The stock is 18% below its 20 day and 42% below its 50 day average. Momentum is fading (RSI 36), near oversold. The nearest support is the swing low (Oct 30) at $5.01, and the nearest resistance the Pivot at $5.16.
| RSI (14) | 36.01 | Weak, oversold below 30 | Neutral |
| MACD | -0.50 | Above its signal line | Bullish |
| Stochastic | 28.5 | Middle of its range | Neutral |
| ADX (14) | 19.1 | No clear trend | |
| Williams %R | -89.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -106.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −7.2% | Change over 10 sessions | Bearish |
| ATR (14) | $0.67 | Typical daily range, 12.9% of price |
| RSI (14) | 31.48 | Weak, oversold below 30 | Neutral |
| MACD | -1.48 | Below its signal line | Bearish |
| Stochastic | 7.2 | Near the bottom of its range | Oversold |
| ADX (14) | 13.3 | No clear trend | |
| Williams %R | -97.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -128.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −42.4% | Change over 10 sessions | Bearish |
| ATR (14) | $1.81 | Typical daily range, 35.0% of price |
What happened before
See how EIKN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in EIKN in the last 90 days.
EIKN Institutional Ownership
Full report →- ▲74 buying vs 18 selling
- ▲Shares held by funds +19.5%
- ▲Funds holding +21
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 98 | 77 | +27.3% |
| In funds' top 10 | 4 | 5 | −20.0% |
| Held by funds | – | – | – |
| New / increased | 30 / 44 | 37 / 17 | +37.0% |
| Reduced / sold out | 9 / 9 | 9 / 12 | −14.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EIKN is in one of them and how their past EIKN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EIKN in an article yet. Here's the latest on the wider market.
About Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company based in Millbrae, California, that is developing medicines for cancer. Its main focus is oncology, and its most advanced candidate, EIK1001, is in Phase 2/3 trials with pembrolizumab for advanced melanoma. The company also has candidates that inhibit PARP1 for ovarian, breast, prostate and pancreatic cancers, plus an early-stage helicase inhibitor. Its medicines are still in clinical development and are not yet sold to patients.
- Headquarters
- Millbrae, CA


